Our Trustees

Mark is a consultant to the pharmaceutical industry. Previously, he spent 30 years in the City as an equity research analyst covering the pharmaceutical and biotech sectors. In addition to his consulting activities, Mark has volunteered for several health-related not-for-profit organisations and was a Trustee of the international health NGO, Malaria Consortium between 2016-2021.

Trevor Back is a product manager at DeepMind where his role focuses on the translation of artificial intelligence to real-world problems in consumer, automotive, deep tech, and healthcare industries. Trevor was a founding member of DeepMind Health where he lead the research team to multiple Nature publications. Before DeepMind, he completed a Ph.D. in computational astrophysics at the University of Edinburgh.

Jonathan has worked in fundraising roles across the charity, Arts and higher education sectors over the last 33 years – for causes as varied as mental health, breast cancer and the environment to Cambridge University, where he was part of the small team that delivered Europe’s first billion-pound campaign. He is currently working as a fundraising consultant, supporting Arts and education clients alongside serving as Chief Executive of The Little Foundation.

Richard trained as a lawyer, was admitted to the bars of New York and the District of Columbia and practised law for 5 years. Following this he spent 23 years as an investment banker in London and New York specialising in mergers and acquisitions and was involved in some of the largest cross-border transactions of the period. He has been active as a trustee in the charity sector for the last 15 years. He was a Fellow and Chair of the Investment Committee of Balliol College, Oxford University. He also served as a non-executive director of OXIP, an investment fund managing assets for charities, university endowments and pension funds.

Louisa Fleure is Urology Consultant Nurse at Guy’s and St Thomas’ NHS Trust, London. She has authored several publications on urology and prostate cancer and presented at regional, national and international meetings on these topics. Louisa has served as trustee for the British Association of Urological Nurses (BAUN) and held the posts of Secretary, Treasurer and Conference Lead.

Louisa specialises in the care of men with advanced prostate cancer with a special interest in androgen deprivation therapy. Her work and dedication in the field of advanced prostate cancer has been widely acknowledged and has included: the Lynn Adams Award for leadership and innovation in cancer nursing (2014), runner up in the BJN urology nurse of the year (2015), 2016 BAUN Urology Team of the Year, finalist in oncology quality in Care Awards: prostate cancer survivorship team (2016), and the Nightingale Award (2018). She was awarded The Urology Foundation/BAUN’s ‘Urology Nurse of the Year’ award in November 2019 for her work in providing information and support to men with advanced prostate cancer

Louisa is chair of the prostate Special Interest Group for the European Association of Urological Nurses.

Shaun Grady is Vice-President Business Development Operations at AstraZeneca. His career background includes roles at ICI, Zeneca, and AstraZeneca in Corporate, Pharmaceuticals and US Legal departments, HR and Business Development. Shaun has worked on major projects including the AstraZeneca merger, creation of Avecia and Syngenta, acquisition of Cambridge Antibody Technology (CAT), MedImmune and Amylin, and the spin out of Albireo.

Ben Monro-Davies is a TV journalist currently working for Sky News. He has 20 years’ experience of news production. He launched All Out Politics with Adam Boulton, and was part of the launch team for Sky News at Ten. He also oversaw the 2012 relaunch of Channel 4 News, and oversaw special BBC1 programmes to mark the beginning and the conclusion of the EU referendum campaign. He has worked closely with many of the broadcasting world’s leading journalists.

Dr. Suman Shirodkar, is a physician-scientist motivated by transformative science leading to significant patient benefit and commercially successful products. She has management consulting expertise, having led consulting engagements at McKinsey, and broad commercial experience in oncology, HIV and cardiovascular areas from previous roles at Pfizer and Novartis. She is now Chief Executive Officer at Cambridge Epigenetix Ltd. Suman has a Bachelor of Medicine & Bachelor of Surgery from the University of Bombay and competed a PhD in Virology at Harvard University.

It was during Marcella’s experience of caring for her father, who had been diagnosed with prostate cancer, that Marcella realised the lack of culturally sensitive cancer support, together with the lack of awareness about cancer within the Black African, Black Caribbean and other culturally diverse communities. With over 14 years’ experience in the voluntary/charity sector, Marcella founded Can-Survive UK (CSUK). Based in Manchester, CSUK provides culturally sensitive support for people affected by cancer. Marcella is instrumental in the design, coordination and delivery of several cancer related campaigns working in partnership with mainstream cancer organisations and statutory health providers. She also sits on various cancer related Boards and committees. Marcella’s experience of losing her parents to cancer, drives her passion to address the cancer inequalities experienced by, and the lack of culturally appropriate cancer support services for Black African, Black Caribbean and other culturally diverse populations.

Simon Crabb is a Professor of Experimental Cancer Therapeutics at the University of Southampton and an Honorary Consultant in Medical Oncology at University Hospital Southampton which includes a large practice in advanced prostate cancer. His research interests focus on developing novel treatment strategies for cancer including precision medicine approaches for prostate cancer. Simon is the Associate Clinical Director of Southampton Clinical Trials Unit and Clinical Programme Lead for Southampton Experimental Cancer Medicine Centre. Other roles have included membership of the NCRI Prostate Group, Trustee of the British Uro-oncology Group, Chairmanship of the Genomics England Clinical Interpretation Partnership for bladder cancer, participation on grant funding committees for multiple organisations including Cancer Research UK and as Associate Editor for the British Journal of Cancer.

Karen Blyth is Professor of In Vivo Cancer Biology at the CRUK Scotland Institute. She is a research scientist who did her PhD at the University of Glasgow, and has spent her career studying cancer biology, including in breast and prostate cancer. Her research contribution, cross cutting cancer biology themes, has made a significant impact to discovery science published in >130 scientific papers. Karen has participated in several network grants, and leads the MRC National Mouse Genetic Network Cancer Cluster. She has sat on grant funding committees for Breast Cancer Now, CRUK and INSERM, and is an Associate Editor for Gene and Scientific Reports, as well as being an ardent advocator for public and patient engagement.

Nick is the founder of Soho House and has been a member of the Soho House & Co Board since its inception. He opened Cafe Boheme on Old Compton Street in 1992 in London’s Soho, and went on to open the first House, Greek Street, in the space above in 1995. Nick has overseen every step of the growth of Soho House & Co. He was awarded an MBE in the Queen’s 2017 New Year’s Honours List.

Alex is Director of International Government Affairs at the global pharmaceutical company Gilead Sciences, focusing on oncology and HIV. He has previously worked for the Labour Party as the Senior Adviser to the Shadow Health and Social Care Secretary and at the Royal College of Nursing. Alex has also worked across the pharmaceutical industry, most recently as Director of Government Affairs and NHS Partnerships for the UK, Ireland, Nordics and Baltics at Novartis, where he was also elected Chair of the Industry Vision Group. Outside of healthcare, Alex has also served on the Confederation of British Industry (CBI) Under 35 Committee.

Magnus has 25 years’ experience in Human Resources roles within GSK, where he is currently the Head of Human Resources for GSK’s Global Research and Development organisation. He is an experienced member of multiple business leadership teams at both regional and global level, leading organisational people priorities focussed on talent, capability, leadership and cultural change.

Matt joined the Board of Trustees in 2016 and served as Chair from 2018-2024, during which time PCR awarded more than £7.5m of grant funding. A founding member of the financial advisory firm Robey Warshaw, Matt advised on many of the largest UK M&A transactions. Matt is Chair of Kidney Research UK and a Non-Executive Director at the Wellcome Sanger Institute and of ConstructiveBio. Although Matt has stepped down as Chair, we are delighted that he continues to support PCR, including as a member of the Finance, Audit & Risk Committee of the Board and as a member of the TSAC (Translational Science Advisory Committee).

Ameet advises a range of businesses and investors on UK and international politics, including helping them navigate complex policy problems. He is Founder of Hanbury Strategy, a strategic advisory firm that provides political analysis, develops communications strategies and uses cutting edge data and research to understand public opinion. Prior to founding Hanbury, he was Chief Speechwriter, Director of Strategic Communications and Director of Strategy to Prime Minister David Cameron. He has been described by the Mail on Sunday as ‘the most influential figure from an ethnic minority background in British politics’.